The cover story focuses on the first FDA-approved gene-transfer therapy, Novartis’s Kymriah, and other CAR T-cell products in development.

 Breakthrough for Industry and Patients

Cover Story: On 30 August, the FDA approved Novartis’s Kymriah, the first gene therapy for the treatment of pediatric and young-adult patients with relapsed and refractory ALL. This is the first FDA-approved gene-transfer therapy, but there are a number of other CAR T-cell products in development.

Patent Battles in the Age of CRISPR

Feature: CRISPR’s power lies in its relative simplicity and precision, and it is expected to have profound implications for agriculture and the treatment of disease.

Setting the Course for Biopharma’s Future

Special Report: While biopharmaceutical drugs have become standard therapy for multiple diseases, they require new manufacturing techniques both at the facility and throughout the supply network.